Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rhythm Pharmaceuticals Inc.

www.rhythmtx.com

Latest From Rhythm Pharmaceuticals Inc.

Keeping Track: Biosimilars, Novel Approvals, And Ebola

The latest drug development news and highlights from our US FDA Performance Tracker include a Neulasta biosimilar approval for Sandoz, novel approvals for Celgene's Reblozyl and Giskit B.V.'s ExEm Foam, and a submission for Regeneron's Ebola candidate.

US FDA Performance Tracker Approvals

Finance Watch: Phathom IPO Meets Pricing Goal; Cabaletta, TFF Offerings Go Low

Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.

Financing Business Strategies

Rhythm Preparing NDA Submission In Rare Genetic Obesity Disorders

Setmelanotide reduced feelings of hunger in patients with POMC and LEPR deficiency obesities and helped many lose weight, with some caveats across certain endpoints.

Clinical Trials Rare Diseases

Finance Watch: Is The IPO Boom Making Anyone Nervous Yet?

Public Company Edition: Is the IPO bubble getting ready to burst? It's anybody's guess, but biopharma companies are forging ahead, having launched 11 first-time offerings during the past week and a half. Also, Heron leads recent follow-on offerings with a $200m stock sale to fund what may soon be its third commercial product.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • 1649904
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Rhythm Pharmaceuticals Inc.
  • Senior Management
  • Keith M Gottesdiener, MD, CEO
    Hunter Smith, CFO
    Murray W Stewart, MD, CMO
    Nithya Desikan, Chief Commercial Officer
  • Contact Info
  • Rhythm Pharmaceuticals Inc.
    Phone: (857) 264-4280
    222 Berkeley St., 12th Fl.
    Boston, MA 02116
    USA
UsernamePublicRestriction

Register